AVIRAtea Pharmaceuticals, Inc.
$5.15+73% 1Y
$5.15
$2.9652 weeks$6.15
Is it safe?
Watch
2 to watch, 4 without dataCaution warranted: heavy debt (CCC) and big price swings.
Credit gradeCCCderived · Jun 30, 2026
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Drawdown risk47% volderived · Oct 8, 2026
Large price swings, high volatility. Worst drawdown -97% · now 16% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AVIR take a bad year?
The deepest fall in AVIR's price history on file is −97%; it is 16% below its high today.
−97%
Worst drawdown on file · −16% today
- Annualised volatility
- 47%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $219M
- EBITDA, trailing twelve months
- −$183M
- Operating profit, trailing twelve months
- −$184M
- Annualised volatilitytwo years of daily moves
- 47%
- Worst drawdown on file
- −97%
- Below its 52-week high
- 16%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.